Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
1.590
-0.040 (-2.45%)
At close: Aug 6, 2025, 4:00 PM
1.610
+0.020 (1.26%)
After-hours: Aug 6, 2025, 7:57 PM EDT
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 5 analysts that cover Mereo BioPharma Group stock have a consensus rating of "Strong Buy" and an average price target of $7.20, which forecasts a 352.83% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.
Price Target: $7.20 (+352.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +214.47% | Jul 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +340.25% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +340.25% | Apr 9, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $7 | Buy | Initiates | $7 | +340.25% | Mar 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +340.25% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
33.60M
Revenue Next Year
46.49M
from 33.60M
Increased by 38.38%
EPS This Year
-0.05
from -0.29
EPS Next Year
-0.02
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 122.9M | 97.7M | 139.9M | ||
| Avg | 33.6M | 46.5M | 89.6M | ||
| Low | n/a | 1.3M | 23.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 190.6% | 200.9% | ||
| Avg | - | 38.4% | 92.7% | ||
| Low | - | -96.2% | -48.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.05 | 0.06 | 0.02 | ||
| Avg | -0.05 | -0.02 | -0.02 | ||
| Low | -0.07 | -0.06 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.